PD675 - INTERMITTENT FASTING AND CHEMOTHERAPY: FROM FEASIBILITY TO RANDOMIZED CONTROLLED TRIAL AND CLINICAL IMPLEMENTATION

PD675

INTERMITTENT FASTING AND CHEMOTHERAPY: FROM FEASIBILITY TO RANDOMIZED CONTROLLED TRIAL AND CLINICAL IMPLEMENTATION

S. H. Brunvoll^1,2,*, V. F. Nes³, A. Dale⁴, B. Beichmann¹, K. Huseby¹, G. Mackeviciute¹, H. M. Z. Hareide¹, I. H. E. Bergan¹, U. M. Fagerli^3,5, C. Henriksen¹, A. Høidalen⁶, N. S. Warmbrodt⁶, A. Fosså⁷, H. K. Ruud⁴, T. R. Balstad^3,5,8, I. O. Ottestad^1,6

¹Department of Nutrition, University of Oslo, ²Department of Microbiology, Oslo University Hospital, Oslo, ³Cancer Clinic, St. Olavs Hospital, University Hospital, Trondheim, ⁴Department of Clinical nutrition, Akershus University Hospital, Lørenskog, ⁵Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, ⁶Department of Clinical Service, Division of Cancer Medicine, ⁷Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, ⁸Department of Clinical Medicine, Clinical Nutrition Research Group, The Arctic University of Norway, UiT, Tromsø, Norway

Rationale: Intermittent fasting (IF) during chemotherapy may protect normal cells and increase treatment efficacy by sensitizing cancer cells. Before routine use, robust safety and feasibility data, a predefined randomized controlled efficacy trial (RCT) and a pragmatic implementation strategy are needed.

Methods: ONCOFAST is an ongoing multicentre randomized feasibility trial in adults (18–80 years, BMI ≥18.5 kg/m²) with newly diagnosed diffuse large B‑cell or Hodgkin lymphoma at three Norwegian hospitals. Patients are randomized 1:1 to IF (0 kJ for 24h before-24h after each chemotherapy cycle) or standard care. During/between chemotherapy cycles we collect data on dietary intake, anthropometry, quality of life, nutrition impact symptoms and blood/feces. Primary outcomes are safety, feasibility, and acceptability of IF with chemotherapy. Feasibility results will guide endpoints, sample size, and eligibility criteria for a subsequent RCT. We will develop an “IF compliance package” for clinical implementation.

Results: The ONCOFAST study is ongoing. Preliminary data (n=3, mean age 55.3 ± 21.4 years, baseline BMI 22.4 ± 2.8 kg/m²) show mean intakes of 28.7 ± 2.9 kcal/kg/day and 1.3 ± 0.2 g protein/kg/day between cycles (mean 7.0 ± 1.7 days). Patients remained weight stable throughout chemotherapy treatment (mean change 0.7 ± 1.9 kg).

Conclusion: Preliminary results indicate adequate energy and protein intake and stable weight during treatment, suggesting these lymphoma patients may be suitable for IF during chemotherapy. The poster will present the ONCOFAST study design and updated results on safety, feasibility, acceptability, nutritional intake and body weight in all enrolled patients (minimum n=6), as well as the framework for a multicentre RCT and a clinical implementation strategy for scalable use of IF as a nutritional adjunct in routine lymphoma care.

Disclosure of Interest: S. Brunvoll: None declared, V. Nes: None declared, A. Dale: None declared, B. Beichmann: None declared, K. Huseby: None declared, G. Mackeviciute: None declared, H. Hareide: None declared, I. Bergan: None declared, U. Fagerli: None declared, C. Henriksen: None declared, A. Høidalen: None declared, N. Warmbrodt: None declared, A. Fosså Grant / Research Support from: Institution: Takeda, Roche; Advisory role: Takeda, Kite Gilead, and Abbvie, Other: honoraria: BMS, Kyowa Kirin, MSD, Eusa Pharma, Takeda, J&J, Roche, Abbvie, Kite Gilead, H. Ruud: None declared, T. Balstad: None declared, I. Ottestad: None declared